Evotec
Florian Lauck has a diverse work experience spanning multiple roles in software development and scientific research. Florian is currently a Lead Software Developer at Evotec. Prior to this, they worked as a Software Engineer at the Center for Free-Electron Laser Science Hamburg, where they developed and maintained software for X-ray imaging experiments. Florian also served as a Supervisor of Software Development and Senior Software Development Engineer at PerkinElmer, Inc., leading teams in the development of web- and cloud-based software for data management and high-throughput analysis. Additionally, they worked as a Wissenschaftlicher Mitarbeiter at the University of Hamburg, where they developed new methods for computer-based drug design. Florian has also held positions at Fachgruppe Bioinformatik, UCSF, and Saarland University, where they contributed to projects involving web development, scientific software development, and multi-particle simulations. Overall, Florian Lauck has a strong background in software development and scientific research, with expertise in various fields such as drug design, molecular simulation, and enzyme classification.
Florian Lauck holds a Doctorate (Dr. rer. nat.) in Computer Science from the University of Hamburg, which they obtained from 2012 to 2016. Prior to that, they completed a Master's degree (M.Sc.) in Bioinformatics from the Universität des Saarlandes in 2007 and a Bachelor's degree (B.Sc.) in the same field from the same university in 2006.
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.